Commentary on the endocrine society clinical practice guideline on the “treatment of hypercalcemia of malignancy in adults”
Loading...
Files
Date
Journal Title
Journal ISSN
Volume Title
Publisher
W.B. Saunders
Abstract
Description
Keywords
Antiresorptive therapy, Bisphosphonate, Calcimimetics, Calcitonin, Clinical practice guidelines, Denosumab, Evidence-to-decision framework, Grade methodology, Hypercalcemia of malignancy, Knowledge gaps, Refractory, Adult, Bone density conservation agents, Humans, Hypercalcemia, Neoplasms, Bisphosphonic acid derivative, Calcimimetic agent, Calcitriol, Furosemide, Glucocorticoid, Hydrocortisone, Osteoclast differentiation factor, Pamidronic acid, Prednisone, Receptor activator of nuclear factor kappa b, Salcatonin, Zoledronic acid, Bone density conservation agent, Acute phase response, Article, Calcium blood level, Calcium urine level, Clinical practice, Congestive heart failure, Endocrine system, Evidence based practice, Femur fracture, Fracture, Glomerulus filtration, Glomerulus filtration rate, Grade approach, Headache, Human, Hyperglycemia, Hypertension, Hypervolemia, Hypocalcemia, Kidney failure, Knowledge gap, Lymphoma, Medical society, Mental health, Multiple myeloma, Nausea, Osteoclastogenesis, Paraneoplastic hypercalcemia, Parathyroid carcinoma, Practice guideline, Primary hyperparathyroidism, Quality of life, Randomized controlled trial (topic), Side effect, Tachyphylaxis, Urine, Vomiting, Workflow, Complication, Neoplasm